mad0004j08
mAbexperimentalCOVID-19
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2021 (NCT04932850)
Timeline
Indications
Studied for
Mechanism of action
- Spike glycoproteinANTAGONIST
Spike glycoprotein antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04952805 | Phase 2/Phase 3 (Phase 3) | Jun 6, 2021 | Istituto Nazionale Malattie Infettive Lazaro Spallanzani, Toscana Life Sciences Sviluppo s.r.l. |
| NCT04932850 | Phase 1 | Mar 1, 2021 | Cross Research S.A., Toscana Life Sciences Sviluppo s.r.l. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Toscana Life Sciences Sviluppo s.r.l. | For profit | 2 | 2 | 2 | 2021 |
| Cross Research S.A. | For profit | 1 | 0 | 1 | 2021 |
| Istituto Nazionale Malattie Infettive Lazaro Spallanzani | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1